Skip to main content

Funding

1R15NS121784 Kim (PI) 12/01/21 – 11/30/24 NIH. Prevention of alpha-synuclein deSUMOylation as a Parkinson’s therapeutic target.

Private Fund Kim (PI) 02/01/19 – 06/30/2025 AptaBio therapeutics Inc. Developing novel NOX inhibitors as potential therapeutics in Parkinson’s disease.

3P20GM103446-23S6      Kim (Project Lead)        05/01/24 – 04/30/25 NIH. Development of peptide-based imaging targeting VEGFR3 in Parkinson’s pathology

 

P20GM139760       Kim (Project Lead)       02/01/23 – 01/31/25 (NCE) NIH. Senolytics and Exercise Alleviate Aging-Related Parkinson’s and Bone Diseases.